Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 CAD | +1.34% | +0.27% | -4.56% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 609.3 | 448.6 | 385 | 234.8 | 95.55 | 86.62 | - | - |
Enterprise Value (EV) 1 | 681.9 | 448.6 | 385 | 234.8 | 95.55 | 86.62 | 86.62 | 86.62 |
P/E ratio | -29.3 x | -29.4 x | -28.9 x | -9.93 x | -3.51 x | -4.56 x | -6.48 x | -4.69 x |
Yield | - | - | - | - | - | 5.36% | - | - |
Capitalization / Revenue | 11.2 x | 8 x | 6.42 x | 3.82 x | 1.51 x | 1.49 x | 1.34 x | 1.26 x |
EV / Revenue | 11.2 x | 8 x | 6.42 x | 3.82 x | 1.51 x | 1.49 x | 1.34 x | 1.26 x |
EV / EBITDA | 19.3 x | 18.6 x | 14.6 x | 9.85 x | 4.54 x | 5.27 x | 4.23 x | 5.13 x |
EV / FCF | - | 48.2 x | 30.6 x | 13.9 x | - | 12.4 x | - | - |
FCF Yield | - | 2.07% | 3.26% | 7.2% | - | 8.08% | - | - |
Price to Book | - | 2.66 x | - | 1.87 x | - | 1.07 x | 1.13 x | - |
Nbr of stocks (in thousands) | 31,059 | 31,744 | 32,451 | 32,384 | 32,071 | 31,815 | - | - |
Reference price 2 | 19.62 | 14.13 | 11.86 | 7.250 | 2.979 | 2.723 | 2.723 | 2.723 |
Announcement Date | 3/19/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 54.16 | 56.11 | 60.01 | 61.47 | 63.07 | 58.06 | 64.72 | 68.8 |
EBITDA 1 | 31.64 | 24.14 | 26.33 | 23.83 | 21.05 | 16.45 | 20.48 | 16.9 |
EBIT 1 | -4.628 | -12.09 | -6.284 | -13.5 | -10.35 | -14.5 | -13 | -11.1 |
Operating Margin | -8.55% | -21.54% | -10.47% | -21.96% | -16.41% | -24.97% | -20.09% | -16.13% |
Earnings before Tax (EBT) 1 | - | -16.3 | -11.81 | -23.72 | -27.8 | -24 | -22.6 | -20.7 |
Net income 1 | -19.55 | -15.33 | -13.12 | -23.6 | -27.53 | -18.32 | -13.36 | -18.6 |
Net margin | -36.1% | -27.32% | -21.86% | -38.39% | -43.65% | -31.54% | -20.64% | -27.03% |
EPS 2 | -0.6700 | -0.4800 | -0.4100 | -0.7300 | -0.8500 | -0.5967 | -0.4200 | -0.5800 |
Free Cash Flow 1 | - | 9.308 | 12.56 | 16.9 | - | 7 | - | - |
FCF margin | - | 16.59% | 20.93% | 27.49% | - | 12.06% | - | - |
FCF Conversion (EBITDA) | - | 38.56% | 47.7% | 70.92% | - | 42.56% | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | 0.1460 | - | - |
Announcement Date | 3/19/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 15.69 | 14.56 | 15.53 | 15.7 | 15.68 | 14.76 | 16.42 | 16.04 | 15.86 | 12.47 | 14.32 | 15.02 | 16.15 | 15.45 | 16.5 |
EBITDA 1 | 6.182 | 6.316 | 6.158 | 6.016 | 5.337 | 5.079 | 5.505 | 5.128 | 5.34 | 2.707 | 3.925 | 4.525 | 5.2 | 4.6 | 4.9 |
EBIT 1 | -2.392 | -2.886 | -3.561 | -2.943 | -4.107 | -3.185 | -2.998 | -3.06 | -1.106 | -3.468 | -3.8 | -3.7 | -3.5 | -3.6 | -3.3 |
Operating Margin | -15.25% | -19.83% | -22.93% | -18.74% | -26.2% | -21.58% | -18.26% | -19.08% | -6.97% | -27.8% | -26.53% | -24.63% | -21.67% | -23.3% | -20% |
Earnings before Tax (EBT) 1 | -3.517 | -3.551 | -9.146 | -4.501 | -6.524 | -5.832 | -9.32 | -7.325 | -5.326 | -6.135 | -6.1 | -6 | -5.8 | -6 | -5.7 |
Net income 1 | -4.188 | -3.616 | -9.143 | -4.41 | -6.429 | -5.792 | -9.437 | -6.901 | -5.401 | -6.106 | -5.8 | -5.7 | -5.5 | -5.7 | -5.4 |
Net margin | -26.69% | -24.84% | -58.87% | -28.08% | -41.01% | -39.25% | -57.48% | -43.03% | -34.05% | -48.95% | -40.49% | -37.94% | -34.06% | -36.89% | -32.73% |
EPS 2 | -0.1300 | -0.1100 | -0.2800 | -0.1400 | -0.2000 | -0.1800 | -0.2900 | -0.2100 | -0.1700 | -0.1900 | -0.1800 | -0.1650 | -0.1450 | -0.1800 | -0.1700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/17/22 | 5/5/22 | 8/11/22 | 11/10/22 | 3/16/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/14/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | 72.6 | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.294 x | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | 9.31 | 12.6 | 16.9 | - | 7 | - | - |
ROE (net income / shareholders' equity) | - | -8.83% | - | -16.5% | - | -15.5% | -6.8% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 5.320 | - | 3.870 | - | 2.540 | 2.400 | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | 0.94 | - | 0.05 | - | - | - | - |
Capex / Sales | - | 1.67% | - | 0.07% | - | - | - | - |
Announcement Date | 3/19/20 | 3/18/21 | 3/17/22 | 3/16/23 | 3/14/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.56% | 86.87M | |
+23.92% | 74.5B | |
-2.46% | 24.24B | |
+10.52% | 8.45B | |
+4.65% | 8.44B | |
-21.71% | 7.65B | |
+11.90% | 5.24B | |
+2.27% | 4.14B | |
-4.23% | 3.95B | |
+5.42% | 3.83B |
- Stock Market
- Equities
- HLS Stock
- Financials HLS Therapeutics Inc.